Archive for December, 2007
FDA To Extend Review of Data Quality of Genta’s Genasense in Melanoma
Closed Published by Staff Writer December 21st, 2007 in UncategorizedGenta (NASDQ: GNTA) announced today that the company has received notice from the FDA that the FDA has extended its review period of Genta’s request for correction of certain information that was filed pursuant to the information Quality Act for an additional 60 days. The requested correction is related to the FDA’s assessment of progression-free survival in […]
Regeneron Closes $312 Common Stock Sale with Sanofi-Aventis
Closed Published by Staff Writer December 21st, 2007 in biotechRegeneron Pharmaceuticals Inc (NASDQ: REGN) announced today that the company closed the sale of 12 million newly issued shares of Regeneron common stock to the Sanofi-Aventis Group (NYSE: SNY)at a price of $26.00. This announcement follows early termination of the Hart-Scott-Rodino waiting period.
The equity investment is part of a strategic partnership between the two companies entered into […]
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Cancer Drugs
Closed Published by Staff Writer December 20th, 2007 in biotechHuman Genome Sciences (NASDQ: HGSI) and Aegera Therapeutics Inc. announced an agreement where HGS has acquired exclusive worldwide rights (excluding Japan for the development and commercialization of AEG40826 and related compounds. AEG408256 is considered a potent small-molecule inhibitor of multiple IAP (inhibitors of apoptosis) and is expected to begin clinical trials in oncology in early […]
Flamel and Merck Serono to Develop Extended Release Formulation of Therapeutic Proteins
Closed Published by Staff Writer December 20th, 2007 in generalFlamel Technologies (Nasdaq:FLML) and Merck Serono (a division of Merck KGaA) announced that they have entered into a collaboration to investigate the applicability of Flamel’s Medusa(R) technology for the extended release of a therapeutic protein of Merck Serono’s portfolio. Under the terms of the agreement, Flamel will receive an upfront payment of EUR 2 million to […]
Keryx Biopharmaceuticals recently announced that the Independent Data Safety Monitoring Committee raised no safety concerns related the ongoing phase III trial of its lead drug candidate Sulonex. Keryx is currently conducting phase III and IV studies under a Special Protocol Assessment with the FDA. Sulonex (sulodexide oral gelcap) is being investigated to treat diabetic nephropathy, and given the […]
What Does Sanofi-Aventis See In Regeneron?
Closed Published by Michael Bryan December 5th, 2007 in biotechGiven the recent announcement of a partnership between Regeneron and Sanofi-Aventis that could be worth a billion dollars to Regeneron, we wanted to take a closer look at what Regeneron brings to the table. The partnership will give Sanofi access to Regeneron’s Veloci suite (this suite of technologies allows the rapid exploration and validation of […]
